Moderna submits IND application for mRNA-3704.
Methylmalonic Acidemia: An IND application has been submitted to the FDA for mRNA-3704, Moderna's development candidate for MMA. If approved, this will be Moderna's first rare disease program to advance into clinical trials. The Company plans to conduct an open-label, multi-center, dose escalation Phase 1/2 study of multiple ascending doses of mRNA-3704 in pediatric patients with isolated MMA due to MUT enzyme deficiency. The objectives of the study are to evaluate safety and tolerability. mRNA-3704 has received Rare Pediatric Disease Designation by the FDA and Orphan Drug Designation by both the FDA and the European Medicines Agency. Propionic Acidemia: mRNA-3927 was granted Orphan Drug Designation by the FDA in December 2018 and Rare Pediatric Disease Designation by the FDA in January 2019. PA is a rare, life-threatening, inherited metabolic disorder due to a defect in the mitochondrial enzyme propionyl-CoA carboxylase, or PCC. It primarily affects the pediatric population and there is no approved therapy. Moderna is continuing to advance mRNA-3927 in pre-clinical studies. Moderna also continues to enroll patients in a global natural history study of MMA and PA designed to identify and correlate clinical and biomarker endpoints for these disorders. This is a global, multi-center, non-interventional study for patients with confirmed diagnosis of MMA due to methylmalonyl-CoA mutase deficiency or PA.
|Printer friendly Cite/link Email Feedback|
|Date:||Jan 8, 2019|
|Previous Article:||ePlus, Intel and Surgical Theater partner for VR surgical imaging.|
|Next Article:||Great Panther Silver reports Q4 ore processed in Mexico operations decreased 9%.|